Specifically, these findings support further development of pharmacologic inhibitors of FANCI and the pursuit of clinical trials comparing outcomes in patients with and without FANCI inhibition together with carboplatin or other DNA-damaging chemotherapy in patients with metastatic prostate cancers harboring wild-type p53, which is approximately 40% of castration-resistant metastatic prostate cancers (mCRPC) according to a recent study (60). Here, FANCI is linked to metastatic prostate carcinoma.